BLCO Stock Forecast & Price Target

Bausch & Lomb has raised its 2025 revenue guidance to a range of $5,050-5,150 million, translating to a robust 5-7% constant currency growth. The company anticipates an adjusted EBITDA of $860-910 million, indicating a positive shift from prior estimates, while also expecting $25 million in foreign exchange tailwinds for the full year. Additionally, the prescription growth of MIEBO at 111% year-over-year, alongside a 12% increase in XIIDRA sales, highlights the strength and expanding demand for Bausch & Lomb's diverse product portfolio.

Bausch & Lomb's financial performance reveals mixed results, with 2Q25 revenues of $753 million in Vision Care showing 8% year-over-year growth and $216 million in Surgical with 3% growth, while Pharmaceuticals revenue of $309 million fell slightly short of the $310 million reported in 2Q24. The company faces significant challenges, particularly with its product XIIDRA, which is experiencing pricing pressure, indicating potential difficulties in maintaining profitability in the pharmaceutical segment. Additionally, various risks, including lower product uptake and the inability to secure regulatory approvals or new products, contribute to a cautious outlook, especially given net debt levels and overall performance projections.